Biogen Change In Cash vs Net Income Analysis
BIIB Stock | USD 158.01 2.01 1.29% |
Biogen financial indicator trend analysis is way more than just evaluating Biogen Inc prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biogen Inc is a good investment. Please check the relationship between Biogen Change In Cash and its Net Income accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Change In Cash vs Net Income
Change In Cash vs Net Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biogen Inc Change In Cash account and Net Income. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Biogen's Change In Cash and Net Income is 0.4. Overlapping area represents the amount of variation of Change In Cash that can explain the historical movement of Net Income in the same time period over historical financial statements of Biogen Inc, assuming nothing else is changed. The correlation between historical values of Biogen's Change In Cash and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Change In Cash of Biogen Inc are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Change In Cash i.e., Biogen's Change In Cash and Net Income go up and down completely randomly.
Correlation Coefficient | 0.4 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Change In Cash
Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Biogen Inc financial statement analysis. It represents the amount of money remaining after all of Biogen Inc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most indicators from Biogen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biogen Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. At present, Biogen's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 19.32, whereas Tax Provision is forecasted to decline to about 128.5 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 8.9B | 7.9B | 7.3B | 3.9B | Total Revenue | 11.0B | 10.2B | 9.8B | 10.3B |
Biogen fundamental ratios Correlations
Click cells to compare fundamentals
Biogen Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Biogen fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 27.2B | 24.6B | 23.9B | 24.6B | 26.8B | 28.2B | |
Short Long Term Debt Total | 6.4B | 7.8B | 7.6B | 6.6B | 7.3B | 7.7B | |
Other Current Liab | 3.4B | 3.1B | 2.4B | 2.4B | 1.4B | 945.6M | |
Total Current Liabilities | 4.9B | 3.7B | 4.3B | 3.3B | 3.4B | 3.6B | |
Total Stockholder Equity | 13.3B | 10.7B | 11.0B | 13.4B | 14.8B | 15.5B | |
Property Plant And Equipment Net | 3.7B | 3.8B | 3.8B | 3.7B | 3.7B | 3.9B | |
Net Debt | 3.5B | 6.5B | 5.3B | 3.2B | 6.3B | 6.6B | |
Retained Earnings | 16.5B | 14.0B | 13.9B | 16.5B | 17.6B | 18.5B | |
Cash | 2.9B | 1.3B | 2.3B | 3.4B | 1.0B | 723.1M | |
Non Current Assets Total | 18.9B | 17.7B | 16.0B | 14.8B | 20.0B | 21.0B | |
Non Currrent Assets Other | (3.2B) | (1.4B) | 1.9B | 1.5B | 284.3M | 270.1M | |
Cash And Short Term Investments | 4.5B | 2.6B | 3.8B | 4.9B | 1.0B | 1.5B | |
Net Receivables | 1.9B | 2.3B | 2.0B | 2.1B | 2.1B | 2.2B | |
Common Stock Shares Outstanding | 187.4M | 161.3M | 149.6M | 146M | 145.6M | 283.0M | |
Liabilities And Stockholders Equity | 27.2B | 24.6B | 23.9B | 24.6B | 26.8B | 28.2B | |
Non Current Liabilities Total | 9.0B | 10.2B | 8.6B | 7.9B | 8.6B | 9.0B | |
Other Current Assets | 1.2B | 881.1M | 740.8M | 1.4B | 1.2B | 1.2B | |
Other Stockholder Equity | (3.0B) | (3.0B) | (2.9B) | (2.9B) | (2.7B) | (2.5B) | |
Total Liab | 13.9B | 13.9B | 12.9B | 11.2B | 12.0B | 12.6B | |
Property Plant And Equipment Gross | 3.7B | 3.8B | 3.8B | 3.7B | 6.1B | 6.4B | |
Total Current Assets | 8.4B | 6.9B | 7.9B | 9.8B | 6.9B | 7.2B | |
Accumulated Other Comprehensive Income | (135.2M) | (299M) | (106.7M) | (164.9M) | (153.7M) | (146.0M) | |
Intangible Assets | 3.5B | 3.1B | 2.2B | 1.9B | 8.4B | 8.8B | |
Accounts Payable | 530.8M | 454.9M | 589.2M | 491.5M | 403.3M | 423.5M | |
Short Term Investments | 2.3B | 1.6B | 1.3B | 1.5B | 1.5B | 0.0 | |
Inventory | 804.2M | 1.1B | 1.4B | 1.3B | 2.5B | 2.7B | |
Other Liab | 4.2B | 2.4B | 2.0B | 1.3B | 1.5B | 969.6M | |
Other Assets | 3.2B | 4.2B | 3.4B | 1.7B | 1.9B | 2.0B | |
Long Term Debt | 4.5B | 7.4B | 6.3B | 6.3B | 6.8B | 7.1B | |
Property Plant Equipment | 3.2B | 3.4B | 3.4B | 3.3B | 3.8B | 2.1B | |
Good Will | 5.8B | 5.8B | 5.8B | 5.7B | 6.2B | 3.2B | |
Net Tangible Assets | 4.1B | 1.9B | 2.9B | 5.8B | 6.7B | 4.1B | |
Noncontrolling Interest In Consolidated Entity | (4.1M) | (14.2M) | 63.5M | (9.5M) | (8.6M) | (8.1M) | |
Retained Earnings Total Equity | 16.5B | 14.0B | 13.9B | 16.5B | 18.9B | 11.5B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Biogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biogen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biogen Inc Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.02) | Earnings Share 11.06 | Revenue Per Share 66.122 | Quarterly Revenue Growth (0.03) | Return On Assets 0.0499 |
The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.